Side Effects of Combination Therapy with Epirubicin and Cyclophosphamide in Breast Cancer Patients at General Hospital Jend. Ahmad Yani Metro
DOI:
https://doi.org/10.59141/jiss.v6i7.1799Keywords:
Breast Cancer, Epirubicin, Cyclophosphamide, Combination Therapy, Side Effects, Retrospective Cohort StudyAbstract
Breast cancer is one of the most prevalent types of cancer globally, with a significant impact on women’s health. This study investigates the side effects of combination therapy with Epirubicin and Cyclophosphamide in breast cancer patients at General Hospital Jend. Ahmad Yani Metro. A retrospective cohort study was conducted using secondary data from medical records of 30 breast cancer patients who underwent chemotherapy with this combination therapy during June 2025. The study aimed to identify the onset and frequency of side effects associated with this chemotherapy regimen. The results showed that the most common side effects were hematologic (anemia) and non-hematologic (hair loss), with the onset of symptoms occurring at various stages of treatment. Data was analyzed using descriptive statistics, and findings were presented in frequency distribution tables to facilitate understanding of the side effects experienced by the patients. This study provides valuable insights into the challenges faced by breast cancer patients undergoing combination therapy, offering crucial information for improving patient care and management.
Downloads
Published
2025-07-08
How to Cite
Erdina, E., Retno F, N. ., & Oentari , O. D. . (2025). Side Effects of Combination Therapy with Epirubicin and Cyclophosphamide in Breast Cancer Patients at General Hospital Jend. Ahmad Yani Metro. Jurnal Indonesia Sosial Sains, 6(7), 2234–2240. https://doi.org/10.59141/jiss.v6i7.1799
Issue
Section
Articles
License
Copyright (c) 2025 Erdina Erdina, Na'imatul Retno F, Octaviana Dyah Oentari
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike 4.0 International. that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
